Drug labeling is one of the most important parts of getting a peptide product to market. The FDA has strict rules about what must appear on your label and how it must be presented.
Getting labeling wrong can delay your approval, trigger recalls, or lead to warning letters. This guide covers everything you need to know about peptide drug labeling requirements.
- FDA drug labeling includes package inserts, container labels, carton labels, and patient leaflets, not just the product sticker.
- Peptide drugs require special labeling for storage conditions, reconstitution steps, injection instructions, and immunogenicity warnings.
- The Highlights section of prescribing information is often the only part clinicians read, so accuracy there is critical.
- Labeling errors can delay FDA approval, trigger product recalls, or result in warning letters against your company.
- Post-approval labeling changes follow specific FDA pathways, so build a process for ongoing label maintenance early.
- International markets have different labeling requirements, so plan for regional compliance from the start of development.
What Is Drug Labeling?
When the FDA talks about "labeling," they mean more than just the sticker on a bottle. Drug labeling includes all written materials that come with a drug product.
This includes the package insert (prescribing information), the container label, the carton label, and any patient information leaflets. Even promotional materials can be considered labeling.
For peptide drugs, labeling is especially important because many peptides require special storage and handling. Patients and healthcare providers need clear instructions.
Key Components of Peptide Drug Labels
Every peptide drug label must include specific information. The FDA requires the following elements.
| Label Element | What It Includes |
|---|---|
| Drug Name | Brand name and generic name |
| Dosage Form | Injection, nasal spray, etc. |
| Strength | Amount of active peptide per unit |
| Route of Administration | How the drug is given |
| Quantity | How much is in the package |
| Storage Conditions | Temperature and handling requirements |
| Lot Number | Batch identification |
| Expiration Date | When the product expires |
| NDC Number | National Drug Code |
| Manufacturer Information | Name and address |
The Prescribing Information (Package Insert)
The prescribing information is the most detailed part of drug labeling. It follows a specific format called the Physician Labeling Rule (PLR).
The FDA finalized the PLR in 2006. It requires all prescribing information to use a standard format that makes it easier for doctors to find important information.
Sections of the Prescribing Information
The prescribing information must include these sections in this order.
- Highlights of Prescribing Information
- Full Prescribing Information: Table of Contents
- Full Prescribing Information (detailed sections)
Highlights Section
The Highlights section is a summary of the most important information about the drug. It should be no longer than half a page.
This section includes the drug's indications, dosage, warnings, and the most common side effects. For peptide drugs, it also includes important storage and handling information.
"The Highlights section is often the only part of the label that busy clinicians read. Making it clear and complete is essential for patient safety," notes Dr. Linda Torres, a regulatory labeling specialist with over 20 years of experience in biologics labeling.
Full Prescribing Information Sections
The full prescribing information includes many detailed sections.
- Indications and Usage
- Dosage and Administration
- Dosage Forms and Strengths
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Drug Interactions
- Use in Specific Populations
- Description
- Clinical Pharmacology
- Nonclinical Toxicology
- Clinical Studies
- How Supplied/Storage and Handling
- Patient Counseling Information
Special Labeling Considerations for Peptide Drugs
Peptide drugs have some unique labeling needs that other drugs may not have. Here are the most important ones.
Storage and Handling Instructions
Many peptide drugs need to be kept cold. Your label must clearly state the storage temperature range.
If your peptide drug needs to be kept at 2 to 8 degrees Celsius (refrigerated), this must be on the label in bold or prominent text. Some peptides are even more sensitive and need to be frozen.
According to the World Health Organization, temperature excursions during storage and transport are one of the leading causes of pharmaceutical product degradation worldwide. Peptide drugs are especially vulnerable due to their complex molecular structure.
Reconstitution Instructions
Some peptide drugs come as powders that need to be mixed with a liquid before use. Your label must include detailed reconstitution instructions.
These instructions should cover what liquid to use, how much to add, how to mix it, and how long the reconstituted solution is stable. Include pictures or diagrams if possible.
Injection Instructions
Most peptide drugs are given by injection. Your label needs clear instructions on how to prepare and give the injection.
Include information about injection sites, needle size, and injection technique. If the drug comes in a pre-filled syringe or auto-injector, include device-specific instructions.
Immunogenicity Information
Many peptide drugs can trigger an immune response. The FDA requires you to include information about immunogenicity in your labeling.
This section should describe the incidence of anti-drug antibodies seen in clinical trials. It should also explain how immunogenicity was measured and what it means for patients.
Labeling for Different Distribution Channels
Your labeling needs may differ depending on how your peptide drug is distributed.
| Channel | Special Labeling Needs |
|---|---|
| Hospital/Clinic | Professional use labeling, bulk packaging |
| Retail Pharmacy | Patient-friendly language, medication guide |
| Mail Order | Shipping temperature indicators, cold chain info |
| Specialty Pharmacy | Complex administration instructions |
| International | Multi-language requirements |
The Medication Guide
For some peptide drugs, the FDA requires a Medication Guide. This is a patient-friendly document that explains the drug in simple language.
Medication Guides are required when the FDA decides that patient information is needed to prevent serious adverse effects. They are also required when patient adherence to directions is important for the drug's effectiveness.
When Is a Medication Guide Required?
The FDA may require a Medication Guide for your peptide drug if:
- The drug has serious risks that could affect a patient's decision to use it
- Patient adherence to dosing instructions is critical
- The drug has important information patients need to know before use
Write the Medication Guide at a 6th to 8th grade reading level. Use short sentences, simple words, and plenty of white space.
Labeling Review During FDA Approval
Labeling is reviewed as part of the FDA approval process. The FDA's labeling review can be one of the most time-consuming parts of approval.
Start working on your labeling early. Do not wait until the end of the review process to draft your label. For authoritative context, see the FDA drug labeling requirements.
The Labeling Negotiation Process
During the review, the FDA may ask for changes to your labeling. This back-and-forth negotiation can take several months.
Common areas of disagreement include the wording of warnings, the description of clinical trial results, and the indications statement. Be prepared to provide data to support your proposed language.
For tips on managing the overall regulatory submission process, see our guide on regulatory submission timelines.
Post-Approval Labeling Changes
Your labeling is not set in stone after approval. The FDA may require changes based on new safety information, new clinical data, or other reasons.
Types of Labeling Changes
There are three types of post-approval labeling changes.
- CBE-30 supplements: For changes that add or strengthen a warning, contraindication, or precaution. You can implement these 30 days after submitting to the FDA.
- CBE-0 supplements: For changes to add a warning about a newly identified safety issue. You can implement these immediately upon submission.
- Prior Approval Supplements (PAS): For changes that require FDA approval before implementation, such as adding a new indication.
Managing these changes properly is important. Check out our article on post-approval change management for peptide drugs for more details.
Common Labeling Mistakes to Avoid
Many peptide drug companies make labeling errors that could be easily avoided. Here are the most common ones.
- Using promotional language in the prescribing information
- Not updating labeling after new safety data becomes available
- Missing or incorrect storage conditions
- Inconsistent information between different parts of the label
- Not including required lot numbers or expiration dates
- Using overly complex language in patient materials
- Failing to include device instructions for combination products
International Labeling Requirements
If you plan to sell your peptide drug outside the United States, you need to meet labeling requirements in other countries too.
The EU, Japan, and other major markets each have their own labeling rules. While there are similarities, there are also important differences.
| Requirement | United States | European Union | Japan |
|---|---|---|---|
| Format | PLR Format | SmPC Format | JP Format |
| Language | English | Local language required | Japanese |
| Patient Info | Medication Guide | Package Leaflet (PIL) | Patient Guide |
| Review Body | FDA | EMA/National Agencies | PMDA |
Electronic Labeling
The FDA has been moving toward electronic labeling through the Structured Product Labeling (SPL) format. All drug labeling must be submitted in SPL format.
SPL uses XML coding to structure labeling information. This allows the FDA to store and search labeling data electronically.
Your labeling team needs to be familiar with SPL. If you do not have in-house expertise, consider working with a labeling technology vendor.
Frequently Asked Questions
What font size is required on peptide drug labels?
The FDA requires that the established name (generic name) appear in a font size at least half the size of the brand name. Container labels for small packages must have text that is legible and not smaller than 6 point font. The FDA recommends at least 8 point font for readability.
How often should peptide drug labels be updated?
Labels should be updated whenever new safety information becomes available, when clinical data changes the benefit-risk profile, or when the FDA requires changes. There is no set schedule, but companies should review their labeling at least annually.
Can peptide drug labels include information about off-label uses?
No. Drug labeling can only include information about FDA-approved uses. Including information about off-label uses in the labeling is a violation of FDA rules and could result in enforcement action.
What happens if a peptide drug is mislabeled?
Mislabeled drugs are considered "misbranded" under the Federal Food, Drug, and Cosmetic Act. This can result in product seizures, injunctions, warning letters, or even criminal prosecution. Mislabeling is also a common trigger for drug recalls.
Do peptide research chemicals need FDA-compliant labeling?
Peptide research chemicals that are not marketed as drugs do not need to follow FDA drug labeling rules. However, they must be clearly labeled as "For Research Use Only" and should not make any therapeutic claims.
Who is responsible for peptide drug labeling accuracy?
The drug's manufacturer or marketing authorization holder is ultimately responsible for labeling accuracy. This includes both the content and the physical labeling of the product. Quality control should verify every printed label before it goes on a product.
Final Thoughts
Peptide drug labeling is a complex but essential part of regulatory compliance. Getting it right protects patients, keeps regulators happy, and supports your commercial success.
Start thinking about labeling early in your development process. Work closely with your regulatory team, medical writers, and quality team to make sure every element is correct.
A well-designed label is more than a regulatory requirement. It is a communication tool that helps healthcare providers and patients use your peptide drug safely and effectively.
Topics
Dr. Lisa Park
Regulatory Affairs Specialist
PharmD | 9 years in peptide pharmaceutical compliance
Focuses on FDA, DEA, and state pharmacy board regulations governing peptide compounds. Guides compounding pharmacies and peptide manufacturers through changing compliance landscapes.
Reviewed by Dr. Lisa Park, PharmD, April 2026